solubility of ABT-263 in water, the solubility of ABT-263 in DMSO, the solubility of ABT-263 in PBS buffer, the animal experiment(test) of ABT-263,the in vivo,in vitro and clinical trial test of ABT-263,the cell experiment(test) of ABT-263,the IC50, EC50 and Affinity of ABT-263....
Aim: There is an important literature supporting the role of staging laparoscopy to predict the chances of optimal cytoreduction but its role to screen patient for inclusion in neoadjuvant therapy clinical trial is unknown. We report here the results of screening by laparoscopy for inclusion in a ...
The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens.
CDK7 has become a potential therapeutic target, and CDK7 inhibitors have entered the clinical trial as promising methods for a variety of malignancies. THZ1 is a covalent inhibitor of CDK7, which shows strong antitumor effects in various cancers by inhibition of CDK79,10,11,12,13,14,15,16....
Navitoclax (ABT-263) 是有效,可口服的 Bcl-2 抑制剂,可与Bcl-xL,Bcl-2, Bcl-w等多种Bcl-2家族蛋白结合,Ki 值小于 1 nM.
The combination was also validated by dynamic BH3 profiling in cell lines MM patient samplesex-vivo.Further work is required, in the form of a clinical trial, to validate our hypothesis that this provides a highly effective novel combination therapy option for myeloma patients. Conclusion. BH3 ...
Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
60. This combination offers interesting perspectives for the clinical use of ABT-263 (Navitoclax, the orally available ABT-737 analog). Due to its ability to antagonize the survival function of Bcl-xLin platelets61, Navitoclax triggers thrombocytopenia, which is its major dose-limiting side-effect...
Mechanistically, apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo. Conclusions Our study provides a rationale for the clinical application of ...
FeaturesRe-engineered version of ABT-263 (Navitoclax). Targets Bcl-2[1] (Cell-free assay) <0.01 nM(Ki) In vitro In vitroABT-199 shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Kiof 48 nM, > 444 nM and 245 nM, respectively. ABT-199 potently inhibits FL5.12-Bcl-2 cells,...